Dasanix 100 mg (Tablet)
Unit Price: ৳ 400.00 (3 x 10: ৳ 12,000.00)
Strip Price: ৳ 4,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Dasatinib |
| Company | Beacon pharmaceuticals plc |
| Also available as |
Indications
- Treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML)
- Resistant or intolerant Ph+ CML with prior Imatinib treatment
- Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
- Pediatric patients 1 year of age and older with Ph+ CML
- Newly diagnosed Ph+ ALL in combination with chemotherapy
Pharmacology
- Inhibition of BCR-ABL, SRC family, c-KIT, EPHA2, and PDGFRβ
- Active in leukemic cell lines representing imatinib mesylate-sensitive and resistant disease
- Metabolized primarily by CYP3A4
- Apparent volume of distribution is 2505 (CV% 93%)
- Elimination primarily via feces
Dosage & Administration
- Adult dosage: 100 mg once daily for chronic phase CML, 140 mg once daily for accelerated phase CML or Ph+ ALL
- Pediatric dosage based on body weight: 40-100 mg once daily
- Tablets should not be crushed, cut, or chewed
- Doses can be taken with or without food
Interaction
- CYP3A4 Inhibitors: Avoid concomitant use to prevent increased Dasanix concentrations
- CYP3A4 Inducers: Consider dose increase if concomitant administration cannot be avoided
- Gastric Acid Reducing Agents: Avoid use with H2 antagonists or proton pump inhibitors
Contraindications
- Known hypersensitivity to Dasatinib or any component of the formulation
Side Effects
- Myelosuppression
- Bleeding-related events
- Fluid retention
- Cardiovascular events
- Pulmonary arterial hypertension
- QT prolongation
- Severe dermatologic reactions
- Tumor lysis syndrome
- Effects on growth and development in pediatric patients
Pregnancy & Lactation
- Potential fetal harm when administered to pregnant women
- Use of effective contraceptive methods advised for females of reproductive potential
- Breastfeeding not recommended during treatment and for 2 weeks after final dose
Precautions & Warnings
- Severe thrombocytopenia, neutropenia, and anemia
- Serious and fatal bleeding
- Risk of fluid retention
- Cardiac dysfunction
- Development of pulmonary arterial hypertension
- Risk of QT prolongation
- Severe mucocutaneous dermatologic reactions
- Tumor lysis syndrome risk
Overdose Effects
- Limited experience with overdose
- Severe myelosuppression and bleeding reported in isolated cases
- Close monitoring and supportive treatment required for overdosage
Therapeutic Class
Targeted Cancer Therapy
Storage Conditions
Store below 30°C in a dry place. Protect from light. Keep out of the reach of children.